MedElevator Войти в исследования
← Поиск публикаций

DOI 10.2174/0118715206321313240820101412

Медицинская библиотека · Anti-cancer agents in medicinal chemistry · 2025

Clinical Efficacy and Safety of CD7-Targeted CAR T Cell Therapy for T-cell Malignancies: A Systematic Review and Meta-analysis.

Dashti Mohsen, Habibi Mohammad Amin, Nejati Negar, Robat-Jazi Behrouz, Ahmadpour Mahsa, Dokhani Negar, Nejad Aida Rezaei, Karami Shaghayegh, Alinejad Erfan, Malekijoo Amir H, Ghasemzadeh Afsaneh, Jadidi-Niaragh Farhad

СтатьяСистематический обзорМетаанализПеревод пока не подготовлен

Аннотация

OBJECTIVES

Although T-cell malignancies are relatively less prevalent compared to B-cell malignancies, they are highly malignant, and patients usually have poor prognoses. Employing CD7-targeted chimeric antigen receptor (CAR) T cell therapy as a novel immunotherapy to treat malignant T cells faces numerous challenges and is in its early phase. To evaluate this possibility, we aimed to review and meta-analyze the related clinical trials systematically.

METHODS

On October 9, 2023, the online databases of PubMed, Scopus, Embase, and Web of Science were systematically searched for pertinent studies. After completing a two-step title/abstract and full-text screening process, the eligible studies were included.

RESULTS

We observed a pooled overall response rate (ORR) of 100%. Partial response (PR), stringent and/or complete response (sCR/CR), and relapse rate were 6%, 85%, and 18%, respectively. Additionally, the pooled rate of minimal residual disease (MRD) negativity was 85%. The most common grade ≥3 adverse events were related to hematological toxicities, including neutropenia (100%), thrombocytopenia (79%), and anemia (57%). Cytokine release syndrome (CRS) was also a frequent complication with a 100% rate; however, 81% of CRS events were low grades. No grade ≥3 GVHD was reported, and the immune effector cell-associated neurotoxicity syndrome (ICANS grade ≥3) was rare (4%).

CONCLUSION

CD7 is an active and safe target that shows promising results in the treatment of relapsed and/or refractory (r/r) T-cell malignancies.

Для цитирования: Dashti Mohsen, Habibi Mohammad Amin, Nejati Negar, Robat-Jazi Behrouz, Ahmadpour Mahsa, Dokhani Negar, Nejad Aida Rezaei, Karami Shaghayegh, Alinejad Erfan, Malekijoo Amir H, Ghasemzadeh Afsaneh, Jadidi-Niaragh Farhad. Clinical Efficacy and Safety of CD7-Targeted CAR T Cell Therapy for T-cell Malignancies: A Systematic Review and Meta-analysis.. Anti-cancer agents in medicinal chemistry. 2025. DOI: 10.2174/0118715206321313240820101412.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.